2026 H2 AbbVie China Partnering Day
In 2026, cross-border licensing transactions for innovative drugs in China continued to heat up, and multinational pharmaceutical companies accelerated their efforts to expand their local innovation in China.
Recently, AbbVie, a global research-based biopharmaceutical company, officially announced that the 2026 H2 AbbVie China Cooperation Day will be held on October 28 at the W Hotel in Suzhou. Free registration is now open to domestic innovative biotechnology companies, research institutions and investment institutions.
As a crucial platform for AbbVie to cultivate local innovation in China and build a global R&D collaboration network, the China Collaboration Day has gradually become a key channel for local innovative forces to connect with the global resources of multinational pharmaceutical companies. This year’s event focuses on seven core areas: immunology, oncology, neuroscience, ophthalmology, medical aesthetics, other specialty drugs, and technology platforms, providing innovative pharmaceutical companies, research institutions, and investors with a one-on-one window to connect with global R&D executives.
Why AbbVie?
Four Reasons Why China’s Innovative Forces Attended the Conference
For local innovative companies, choosing a cooperation platform is not about the grandeur of an event, but about whether the partner can truly promote innovation globally. As registration opened for the 2026 H2 China Cooperation Day, AbbVie provided the most compelling answer with a set of key metrics:
A world-class, comprehensive resource network: AbbVie ranks second globally in prescription drug sales in the 2025 Pharmaceutical Executive’s Top 50 Global Pharmaceutical Companies, possessing a complete global resource network covering R&D, registration, and commercialization. Partnering with them means access to top-tier global channels.
The pace of AbbVie China Cooperation Day has accelerated from “once a year” to “twice a year” : the event will be held twice a year in 2026, with the second half of the year taking place in Suzhou for the first time, sending a clear signal of increasing investment in local innovation in China and increasing the frequency of collaborations.
A long-term commitment exceeding $10 billion: To date, AbbVie has established significant partnerships with numerous Chinese companies, including Hisun Pharmaceuticals, Zaijing Pharmaceuticals, Rongchang Biotech, Simcere Pharmaceutical, and Mingji Biotech, with a total value exceeding $10 billion. This underscores AbbVie’s long-term strategic partnership with China’s innovative forces.
In addition, the inaugural AbbVie China Innovation Awards for 2026 have been officially announced, with Ruiao Bio and Xinghe Disai winning the major awards in the therapeutic and medical aesthetic fields respectively, demonstrating AbbVie’s commitment to empowering local innovation at an earlier and deeper level.
A benchmark case focusing on differentiated innovation: In June of this year, AbbVie acquired Apogee Therapeutics for $10.9 billion, becoming one of the largest mergers and acquisitions in the innovative drug sector in the first half of 2026. Its core asset, Zumilikibatra, is a long-acting anti-IL-13 antibody. This case demonstrates AbbVie’s commitment to bringing its most differentiated and competitive innovative products to the global patient market.
What can I gain by attending the conference?
Three key empowerments from top global R&D teams
From global R&D deployment to localized collaborations, AbbVie is opening doors to the world for Chinese innovation through tangible deals and awards. At this year’s Collaboration Day, participating companies can directly engage with AbbVie’s global R&D decision-making network, engaging in in-depth dialogues with leading scientists and external innovation leaders, transforming these exchanges into actionable collaboration opportunities.
One-on-one in-depth discussions: Face-to-face meetings with senior R&D and external innovation leaders at AbbVie to precisely explore innovative ideas and research directions.
Decoding the Collaboration Ecosystem: Gain in-depth understanding of AbbVie’s collaboration and investment models, key therapeutic areas, and global innovation strategy to identify areas of convergence.
Demonstrating corporate value: Presenting the company’s current development status, pipeline, and platform advantages to AbbVie’s R&D and strategy departments, and connecting with top global resources.
Event Information:
Event Date: October 28, 2026 (Wednesday)
Event Location: W Suzhou Hotel, Suzhou, China
How to participate: Registration for the main event (including speeches and discussions) is free. “One-on-one meetings” require separate application and approval (application deadline for one-on-one meetings: September 28, 2026).
Inquiries and Materials: Please send non-confidential introductory materials (slides, posters, or research summaries in English) and related questions to ChinaPartnering@abbvie.com
